Safety and efficacy of perioperative cisplatin/gemcitabine (cis/gem) and durvalumab (durva) for operable muscle-invasive urothelial carcinoma (MIUC): SAKK 06/17.

Richard Cathomas,Sacha I. Rothschild,Stefanie Hayoz,Martin Spahn,Julian Schardt,Roland Seiler,Andreas Erdmann,Stefanie Aeppli,Nicolas Mach,Raeto Strebel,Boris A. Hadaschik,Dominik Berthold,Miklos Pless,Deborah Zihler,Mathias Schmid,Martina Schneider,Zuzanna Maniecka,Ulf Petrausch

Safety and efficacy of perioperative cisplatin/gemcitabine (cis/gem) and durvalumab (durva) for operable muscle-invasive urothelial carcinoma (MIUC): SAKK 06/17.

2021

Richard Cathomas
Sacha I. Rothschild
Stefanie Hayoz
Martin Spahn
Julian Schardt
Roland Seiler
Andreas Erdmann
Stefanie Aeppli
Nicolas Mach
Raeto Strebel
Boris A. Hadaschik
Dominik Berthold
Miklos Pless
Deborah Zihler
Mathias Schmid
Martina Schneider
Zuzanna Maniecka
Ulf Petrausch

430Background: The combination of cisplatin-based chemotherapy with immune checkpoint inhibitors is extensively investigated in urothelial carcinoma. Using this combination in the neoadjuvant setti...

Keywords:

Cancer research
Cisplatin/gemcitabine
Perioperative
Cisplatin
muscle invasive
Durvalumab
immune checkpoint inhibitors
urothelial carcinoma
Chemotherapy
Medicine

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations